Austco Healthcare Limited (AHC) Fair Value & Analysis
Healthcare · AU · Market cap A$89.9M
Fair value as of: Jul 19, 2026
From 24 valuation models · updated 22 days ago
Share price −5.3% over the past month.
A solid business, screening 28% undervalued on our models.
What matters now
- Solid quality (51/100) at a price below fair value, the discount is the argument here, not the business quality.
- Our model range runs from A$0.2210 (bear) to A$0.3740 (bull), base A$0.2975. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 51/100 (solid quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 19, 2026.
How to read this chart
60‑month range A$0.0865 – A$0.4450 · fair‑value band A$0.2210 – A$0.3740 · the A$0.2320 price screens below the A$0.2975 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 19, 2026.
Analysis
Austco Healthcare Limited (AHC) currently trades at A$0.2320, while our model-based Fair Value estimate is A$0.2975, implying the stock looks roughly 28.2% undervalued today. The Quality Score stands at 51/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Austco Healthcare Limited generated revenue of A$92.7M at a net margin of 8.4%. Revenue grew 30.7% year over year. It earns a return on equity of 14.4%. The balance sheet holds a net cash position of A$10.6M. Fundamentals as of Jul 19, 2026
Our scenario range runs from A$0.2210 (bear case) to A$0.3740 (bull case); at A$0.2320, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 48% below its 52-week high and 5% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at 28%, AHC screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models (A$0.4400) versus Asset-Based (A$0.0900). Highest evidence: Growth DCF (80).
Notify me when AHC reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 19, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 55 · Market factors (momentum, volatility) 21
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Austco Healthcare Limited, together with its subsidiaries, engages in the business of development, manufacture, service, supply, and distribution of healthcare communications equipment and software in Australia, New Zealand, Asia, Europe, and North America.
Full company description
Austco Healthcare Limited, together with its subsidiaries, engages in the business of development, manufacture, service, supply, and distribution of healthcare communications equipment and software in Australia, New Zealand, Asia, Europe, and North America. The company offers Tacera, an IP nurse call system; Medicom, a solution for nurse call system; Pulse Mobile which allows staff to manage nurse call functions on the go and trigger workflows remotely; clinical workflow that allows healthcare staff to communicate with ancillary departments, measure adherence to protocol, and control other systems; Built-in RTLS, a nurse call platform; enterprise reporting; and integration services. It is also involved in the marketing, sales, and installation of electronic healthcare communication systems. The company was formerly known as Azure Healthcare Limited and changed its name to Austco Healthcare Limited in November 2020. Austco Healthcare Limited was founded in 1986 and is headquartered in Port Melbourne, Australia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Austco Healthcare Limited reported revenue of A$81.4M in FY2025 versus A$31.3M in FY2021, a compound +27.0%/yr. Reported net income was A$5.9M in FY2025, compounding +14.7%/yr from FY2021.
Watch AHC: get an alert when its fair value changes →
Peer Group
Medical Instruments & Supplies · 203 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.33 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €172.45 | €68.55 | -60% |
| Medline Inc MDLN | $41.11 | $30.15 | -27% |
| Becton, Dickinson and Company BDX | $150.65 | $103.53 | -31% |
| Alcon Inc ALC | $70.26 | $39.78 | -43% |
| ResMed Inc RMD | $203.87 | $187.89 | -8% |
| West Pharmaceutical Services, Inc WST | $353.71 | $143.97 | -59% |
| Straumann Holding STMN | CHF 106.00 | CHF 47.31 | -55% |
| Sartorius Stedim Biotech S.A DIM | €188.50 | €51.16 | -73% |
| Coloplast A/S COLOB | kr 414.00 | kr 382.22 | -8% |
Compare Austco Healthcare Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Austco Healthcare Limited (AHC) overvalued or undervalued?
What is the fair value of AHC?
What is the quality score of AHC?
What is the revenue of Austco Healthcare Limited (AHC)?
What is the net profit margin of AHC?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Austco Healthcare Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.